NCT05636111View on ClinicalTrials.gov

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

July 12, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Ovarian Cancer

Interventions

DRUG

Paclitaxel

Given by (IV) vein

DRUG

Bevacizumab

Given by (IV) vein

DRUG

Lurbinectedin

Given by (IV) vein

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Jazz Pharmaceuticals

All Listed Sponsors

collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER